Author Archives: clinicalaccelerator

Replicor discloses long term functional control of HBV and HDV infection in high proportions of treated patients at EASL 2018

Below, we are re-publishing with permission the press-release issued by Replicor on the 13th of April 2018 MONTREAL, April 13, 2018 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator, Conferences | Leave a comment

ValiSeek – ValiRx unveils positive results from VAL401 Phase II lung cancer trial

Below, we are re-publishing the news issued by ValiSeek on the 12th of December 2017 ValiSeek – Clinical Development Update on VAL401 Dr Suzy Dilly, CEO of ValiSeek provides a positive update on the clinical progress of VAL401, the anti-cancer compound. … Continue reading

Posted in Clinical Accelerator | Leave a comment

Clinical Accelerator announces collaboration with VisCardia for investigating a novel device therapy for chronic heart failure

Kiev, Ukraine – December 11, 2017: Clinical Accelerator, a full-service clinical contract research organization, is pleased to announce it has entered into a collaboration with VisCardia Inc. for conducting clinical studies for its VisONE medical device in the Ukraine. The … Continue reading

Posted in Central and Eastern Europe, ClinAccel.Net, Clinical Accelerator | Leave a comment

Promising Interim Clinical Data for NOX66

Below, we are re-publishing with permission the press-release issued by Noxopharm Limited on the 20th of November 2017 PROMISING INTERIM CLINICAL DATA FOR NOX66 Patients with metastatic, late-stage cancers 10 of 11 patients showing no disease progression following 3-months treatment with NOX66 … Continue reading

Posted in Central and Eastern Europe, Clinical Accelerator | Leave a comment

First Verified Data Release from VAL401 Phase II Clinical Trial

Below, we are re-publishing with permission the press-release issued by ValiSeek on the 28th of September 2017  ValiRx Plc (“ValiRx” or the “Company”) VALISEEK CLINICAL DEVELOPMENT UPDATE “First Verified Data Release from VAL401 Phase II Clinical Trial” London, UK., 28 September … Continue reading

Posted in Clinical Accelerator | Leave a comment

Replicor announces publication of its REP 301 study in HBV / HDV co-infection in The Lancet Gastroenterology & Hepatology

Below, we are re-publishing with permission the press-release issued by Replicor on the 28th of September 2017 MONTREAL, September 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic … Continue reading

Posted in Clinical Accelerator | Leave a comment

Engage with your patients and win greater patient engagement

Part of what makes clinical trials efficient and successful are the smart decisions that are made about protocol design, site selection, staff training, technologies used, information provided and so on. Patients’ motivation for enrolment and perception of clinical trials play … Continue reading

Posted in Patient Enrolment | Leave a comment